WEDNESDAY, SEPTEMBER 28, 2016

MIT develops new paper-based Zika virus test

MIT researchers have led a team in developing a paper-based test that can diagnose the Zika virus in just a few hours.  Read More »

Study shows Zika can be transmitted through sexual contact

A study has confirmed that the Zika virus, known to wreak havoc while masked by mild or no symptoms, can be transmitted not only through bites from infected Aedes mosquito but also via sexual contact. Read More »

Researchers study progression of HIV during early stages of infection

Research from several collaborating laboratories, initiated through the Consortium for AIDS Vaccine Research, examined monkeys exposed to Simian Immunovirus infection to determine what happens during the earliest stages of HIV infection in humans. Read More »

Study shows ethnicity may affect response to flu vaccine

A recent study conducted at the Dana-Farber Cancer Institute shows that the immune response generated by the influenza vaccine may be linked to a person’s ethnic background and similar inherited variables. Read More »

VBI partners with GSK to improve vaccine stability

VBI Vaccines Inc. and GlaxoSmithKline (GSK) Biologicals recently made a partnership to determine how to best improve vaccine stability with VBI’s LPV Platform. Read More »

Massachusetts Medical School identifies new stage of HIV infection

University of Massachusetts Medical School (UMMS) scientists recently detected a new life-cycle stage that is part of HIV infections. Read More »

Harvard team discovers new ways to study viruses

Researchers from Harvard University’s John A Paulson School of Engineering and Applied Sciences have found new ways to study viruses, which may help to create better treatments and vaccines. Read More »

Humans, apes share genes connected to malaria virulence

Scientists from the Harvard TH Chan School of Public Health recently found that malaria parasite molecules share important gene segments with gorilla and chimp malaria parasites. Read More »

Visterra receives contract to develop new treatment for influenza A

Visterra, Inc. has recently received a contract worth up to $204.5 million to further develop its new monoclonal antibody to treat influenza A. Read More »

Alere redoubles efforts with Organization of African First Ladies Against HIV/AIDS

Alere said this week that it is redoubling its commitment to support the Organization of African First Ladies Against HIV/AIDS (OAFLA). Alere, a global leader in rapid diagnostics, aims to help reduce the impact of HIV/AIDS in Africa, specifically mother-to-child transmission. Read More »

Scientists reveal how the flu spreads

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID) and MIT have discovered how the flu virus and its many strains, some of which are more capable of spreading than others, manage to transmit from person to person. Read More »

Agenus Inc. finalizes transaction terms with Oberland Capital

Agenus Inc., an immunology company that discovers and creates novel treatments for diseases like cancer, recently announced that it has finalized its non-dilutive royalty transactions pursuant to a note purchase agreement with Oberland Capital Management LLC, the leader of the investor group. Read More »

Mobile phone records may predict dengue fever epidemics

Harvard T.H. Chan School of Public Health said Monday that its researchers found that mobile phone records may be useful in predicting and timing the geographical spread of dengue fever epidemics. Read More »

VBI Vaccines receives grant to advance RSV candidate

VBI Vaccines Inc. recently received approximately $265,000 in grants to further develop the company’s eVLP Platform, which will be used to create a respiratory syncytial virus (RSV) vaccine candidate. Read More »

Doctors overestimate their Ebola assessment abilities

A recent survey of primary care physicians show that many of them overestimate their own abilities to assess potential Ebola cases and explain the risks of Ebola to their patients. Read More »

Small antibodies suggest vulnerability in parasites that cause diseases

Scientists from Whitehead Institute have found a potential target for drugs that could stop parasites from entering host cells thanks to an enzyme that is important to the parasite’s infectious behavior, especially for malaria and toxoplasmosis. Read More »

Cell phone data to monitor spread of infectious diseases

Vast datasets from tracking mobile phone data could allow health professionals to track the infectious diseases that spread each season. Read More »

Visterra medication proves effective against influenza strains

Visterra Inc., a clinical-stage biotechnology company, recently published data that shows the effectiveness of its VIS410 in protecting people from both seasonal and potentially pandemic influenza strains. Read More »

New England Journal of Medicine reports on PMO-based therapeutic

On Wednesday, the New England Journal of Medicine published clinical data for AVI-7288, a PMO-plus antisense oligonucleotide, demonstrating the drug's safety. Read More »

New Visterra antibody broadly neutralizes dengue virus in studies

Visterra Inc., a clinical-stage biotechnology company, recently announced that its novel antibody known as VIS513 has shown positive results in its preclinical studies, where the antibody broadly neutralized all four dengue virus serotypes. Read More »